Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Ovarian cancer is a leading cause of cancer death in women, often diagnosed at late stages with poor survival rates.
• The tumor microenvironment in ovarian cancer is characterized by immune evasion, necessitating novel therapeutic strategies.
• Immunotherapy, particularly targeting immune checkpoints, offers a promising avenue for enhancing anti-tumor immunity.

Purpose of the Study:

• To review the role of the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis in ovarian cancer immune evasion.
• To explore the potential of PD-1/PD-L1 inhibitors, including combination therapies, for treating ovarian cancer.
• To discuss the involvement of non-coding RNAs in regulating the PD-1/PD-L1 pathway.

Main Methods:

• Literature review of preclinical and clinical studies on PD-1/PD-L1 inhibitors in ovarian cancer.
• Analysis of the PD-1/PD-L1 immune checkpoint mechanism and its regulation by non-coding RNAs.
• Synthesis of current research on immunotherapy efficacy and limitations in ovarian cancer.

Main Results:

• The PD-1/PD-L1 axis is a critical immune checkpoint that suppresses anti-tumor T cell responses in ovarian cancer.
• Inhibitors targeting the PD-1/PD-L1 axis can augment anti-tumor immunity.
• Combination therapies, such as immune checkpoint inhibitors with small molecule inhibitors, demonstrate improved efficacy and safety profiles.

Conclusions:

• Targeting the PD-1/PD-L1 axis represents a significant therapeutic strategy for ovarian cancer.
• Non-coding RNAs play a regulatory role in the PD-1/PD-L1 pathway, offering potential for novel therapeutic interventions.
• Further research and clinical investigations are needed to overcome the limitations of current immunotherapies in ovarian cancer.